{"id":8533,"date":"2018-03-20T15:59:35","date_gmt":"2018-03-20T14:59:35","guid":{"rendered":"https:\/\/www.satt.fr\/satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique\/"},"modified":"2018-03-20T16:27:36","modified_gmt":"2018-03-20T15:27:36","slug":"satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique","status":"publish","type":"post","link":"https:\/\/www.satt.fr\/en\/satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique\/","title":{"rendered":"La SATT IDF Innov soutient la conception d\u2019un vaccin anti-chlamydia, un enjeu mondial de sant\u00e9 publique"},"content":{"rendered":"<p><strong>\u00c0 travers le financement d\u2019un projet de maturation ambitieux avec une \u00e9quipe du Centre de Recherche sur l&#8217;Inflammation (Paris Diderot\/Inserm), IDF Innov accompagne et apporte un soutien financier \u00e0 la conception d\u2019un vaccin anti-chlamydia. Ce projet r\u00e9pond \u00e0 la strat\u00e9gie mondiale du secteur de la sant\u00e9 port\u00e9e par l\u2019OMS (Organisation Mondiale de la Sant\u00e9), qui vise \u00e0 lutter contre les infections sexuellement transmissibles (IST) et qui appelle \u00e0 une action imm\u00e9diate.<\/strong><\/p>\n<p><strong>Une maladie silencieuse qui commence \u00e0 faire du bruit<\/strong><\/p>\n<p>131 millions. C\u2019est le nombre de personnes contractant une infection \u00e0 chlamydia chaque ann\u00e9e dans le monde parmi les 15-49 ans selon l\u2019OMS, et le nombre de cas augmente depuis une quinzaine d\u2019ann\u00e9es.<\/p>\n<p>Cette IST est qualifi\u00e9e de \u00ab\u00a0maladie silencieuse\u00a0\u00bb car la plupart des personnes infect\u00e9es ne pr\u00e9sentent aucun sympt\u00f4me, et ne sachant pas qu&#8217;elles sont atteintes, ne vont pas consulter. De fait, elle reste difficile \u00e0 diagnostiquer, se propage plus facilement et augmente le risque de co-infection avec d\u2019autres IST, telles que le sida.<\/p>\n<p>Caus\u00e9e par la bact\u00e9rie chlamydia, ces infections, pr\u00e9sentes dans le monde entier et plus fr\u00e9quentes dans les Am\u00e9riques et la R\u00e9gion Pacifique Ouest, touchent aussi bien les \u00eatres humains que les animaux.<\/p>\n<p>Bien que l\u2019infection soit facile \u00e0 traiter, elle peut entra\u00eener de s\u00e9rieux probl\u00e8mes de sant\u00e9 si elle n&#8217;est pas d\u00e9cel\u00e9e et trait\u00e9e rapidement. Chez la femme, plus largement touch\u00e9e, l\u2019infection due \u00e0 la chlamydia entra\u00eene des l\u00e9sions qui obstruent les trompes et emp\u00eachent la f\u00e9condation et\/ou l\u2019implantation de l\u2019embryon. Une infection \u00e0 chlamydia non trait\u00e9e peut ainsi d\u00e9clencher des troubles graves tels que la st\u00e9rilit\u00e9 et des grossesses extra-ut\u00e9rines. Elle peut \u00e9galement \u00eatre \u00e0 l&#8217;origine d\u2019autres pathologies comme la c\u00e9cit\u00e9.<\/p>\n<p>L\u2019OMS pr\u00e9conise dans le cadre du projet \u00ab\u00a0Strat\u00e9gie mondiale du secteur de la sant\u00e9 contre les IST 2016-2021\u00a0\u00bb, une vaccination pr\u00e9ventive pour lutter contre les infections \u00e0 chlamydia, or aucun vaccin n\u2019est disponible \u00e0 ce jour.<\/p>\n<p><strong>Une innovation de rupture accompagn\u00e9e par IDF Innov<\/strong><\/p>\n<p>Au cours de l\u2019\u00e9t\u00e9 2013, l\u2019\u00e9quipe d\u2019IDF Innov<sup>1 <\/sup>rencontre Colette Kanellopoulos-Langevin<sup>2<\/sup> et Philippe Verbeke<sup>3<\/sup>, tous deux chercheurs au Centre de Recherche sur l&#8217;Inflammation de la facult\u00e9 de m\u00e9decine de l\u2019h\u00f4pital Bichat \u00e0 Paris, dirig\u00e9 par Renato Monteiro.<\/p>\n<p>Les deux chercheurs travaillent alors sur la cr\u00e9ation d\u2019un vaccin anti-chlamydia sans adjuvant. Classiquement, un vaccin est un produit issu du microbe infectieux qui d\u00e9clenche une m\u00e9moire immunitaire contre ce m\u00eame pathog\u00e8ne. Ainsi entra\u00een\u00e9, le syst\u00e8me immunitaire est ensuite capable, lors d\u2019une infection, d\u2019\u00e9liminer l\u2019agent infectieux, emp\u00eachant la maladie de se d\u00e9velopper. Les chercheurs ont eu l\u2019id\u00e9e d\u2019utiliser une chlamydia tu\u00e9e par des antibiotiques pour constituer le vaccin. Cette approche, totalement nouvelle pour le d\u00e9veloppement d\u2019un vaccin, est une v\u00e9ritable innovation de rupture. IDF Innov a ainsi d\u00e9cid\u00e9 de soutenir le d\u00e9veloppement de la technologie via un projet de maturation d\u00e9marr\u00e9 en 2014.<\/p>\n<p>Les r\u00e9sultats obtenus r\u00e9cemment sont particuli\u00e8rement prometteurs et ont conduit au d\u00e9p\u00f4t d\u2019une demande de brevet. Avec le soutien d\u2019IDF Innov, l\u2019\u00e9quipe de recherche a ainsi pu identifier les modes d\u2019action du vaccin, tester plusieurs voies d\u2019administration du traitement, et \u00e9valuer la m\u00e9moire immunitaire \u00e0 long terme. De fa\u00e7on surprenante, l\u2019\u00e9quipe de recherche a de plus pu d\u00e9montrer que l\u2019injection du vaccin apr\u00e8s infection entra\u00eene une baisse significative de la charge bact\u00e9rienne.<\/p>\n<p>Cela ouvre des perspectives tr\u00e8s encourageantes pour le d\u00e9veloppement d\u2019un vaccin s\u00fbr et efficace \u00e0 la fois sur des personnes saines ou d\u00e9j\u00e0 infect\u00e9es.<\/p>\n<p>&nbsp;<\/p>\n<p><sup>1<\/sup> <strong><em><u>\u00c9quipe IDF Innov <\/u><\/em><\/strong>: Lydie Viatte (Chef de projet), Davide D\u2019Alia (Business Developer), Marion \u00a0\u00a0\u00a0\u00a0Mouton (Ing\u00e9nieur Brevet)<\/p>\n<p><sup>2<\/sup> <strong><em><u>Colette Kanellopoulos-Langevin<\/u><\/em><\/strong><strong><em>\u00a0<\/em><\/strong>: Directrice de Recherche \u00e9m\u00e9rite au CNRS<\/p>\n<p><sup>3<\/sup> <strong><em><u>Philippe Verbeke<\/u><\/em><\/strong> : Ma\u00eetre de conf\u00e9rences \u00e0 l\u2019Universit\u00e9 Paris Diderot<\/p>\n<p>&nbsp;<\/p>\n<p><a href=\"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/03\/CP-Chlamydia_mars2018.pdf\">Le communiqu\u00e9 de presse en pdf<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00c0 travers le financement d\u2019un projet de maturation ambitieux avec une \u00e9quipe du Centre de Recherche sur l&#8217;Inflammation (Paris Diderot\/Inserm), IDF Innov accompagne et apporte un soutien financier \u00e0 la conception d\u2019un vaccin anti-chlamydia. Ce projet r\u00e9pond \u00e0 la strat\u00e9gie mondiale du secteur de la sant\u00e9 port\u00e9e par l\u2019OMS (Organisation Mondiale de la Sant\u00e9), qui [&hellip;]<\/p>\n","protected":false},"author":22,"featured_media":8530,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[567],"tags":[],"class_list":["post-8533","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>La SATT IDF Innov soutient la conception d\u2019un vaccin anti-chlamydia, un enjeu mondial de sant\u00e9 publique - R\u00e9seau SATT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.satt.fr\/en\/satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Estelle VIDAL\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.satt.fr\/en\/satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique\/\"},\"author\":{\"name\":\"Estelle VIDAL\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/f31631111412086f92f3dd2a2e132823\"},\"headline\":\"La SATT IDF Innov soutient la conception d\u2019un vaccin anti-chlamydia, un enjeu mondial de sant\u00e9 publique\",\"datePublished\":\"2018-03-20T14:59:35+00:00\",\"dateModified\":\"2018-03-20T15:27:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique\/\"},\"wordCount\":712,\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/03\/3200x1785.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.satt.fr\/en\/satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique\/\",\"url\":\"https:\/\/www.satt.fr\/en\/satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique\/\",\"name\":\"La SATT IDF Innov soutient la conception d\u2019un vaccin anti-chlamydia, un enjeu mondial de sant\u00e9 publique - R\u00e9seau SATT\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/03\/3200x1785.jpg\",\"datePublished\":\"2018-03-20T14:59:35+00:00\",\"dateModified\":\"2018-03-20T15:27:36+00:00\",\"author\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/f31631111412086f92f3dd2a2e132823\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.satt.fr\/en\/satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.satt.fr\/en\/satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.satt.fr\/en\/satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique\/#primaryimage\",\"url\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/03\/3200x1785.jpg\",\"contentUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/03\/3200x1785.jpg\",\"width\":3200,\"height\":1785,\"caption\":\"Female doctor giving an injection to a patient at the hospital\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.satt.fr\/en\/satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.satt.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La SATT IDF Innov soutient la conception d\u2019un vaccin anti-chlamydia, un enjeu mondial de sant\u00e9 publique\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.satt.fr\/en\/#website\",\"url\":\"https:\/\/www.satt.fr\/en\/\",\"name\":\"R\u00e9seau SATT\",\"description\":\"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.satt.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/f31631111412086f92f3dd2a2e132823\",\"name\":\"Estelle VIDAL\",\"url\":\"https:\/\/www.satt.fr\/en\/author\/estelle\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La SATT IDF Innov soutient la conception d\u2019un vaccin anti-chlamydia, un enjeu mondial de sant\u00e9 publique - R\u00e9seau SATT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.satt.fr\/en\/satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique\/","twitter_misc":{"Written by":"Estelle VIDAL","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.satt.fr\/en\/satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique\/#article","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique\/"},"author":{"name":"Estelle VIDAL","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/f31631111412086f92f3dd2a2e132823"},"headline":"La SATT IDF Innov soutient la conception d\u2019un vaccin anti-chlamydia, un enjeu mondial de sant\u00e9 publique","datePublished":"2018-03-20T14:59:35+00:00","dateModified":"2018-03-20T15:27:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.satt.fr\/en\/satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique\/"},"wordCount":712,"image":{"@id":"https:\/\/www.satt.fr\/en\/satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/03\/3200x1785.jpg","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.satt.fr\/en\/satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique\/","url":"https:\/\/www.satt.fr\/en\/satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique\/","name":"La SATT IDF Innov soutient la conception d\u2019un vaccin anti-chlamydia, un enjeu mondial de sant\u00e9 publique - R\u00e9seau SATT","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.satt.fr\/en\/satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique\/#primaryimage"},"image":{"@id":"https:\/\/www.satt.fr\/en\/satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/03\/3200x1785.jpg","datePublished":"2018-03-20T14:59:35+00:00","dateModified":"2018-03-20T15:27:36+00:00","author":{"@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/f31631111412086f92f3dd2a2e132823"},"breadcrumb":{"@id":"https:\/\/www.satt.fr\/en\/satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.satt.fr\/en\/satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.satt.fr\/en\/satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique\/#primaryimage","url":"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/03\/3200x1785.jpg","contentUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/03\/3200x1785.jpg","width":3200,"height":1785,"caption":"Female doctor giving an injection to a patient at the hospital"},{"@type":"BreadcrumbList","@id":"https:\/\/www.satt.fr\/en\/satt-idf-innov-soutient-conception-dun-vaccin-anti-chlamydia-enjeu-mondial-de-sante-publique\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.satt.fr\/en\/"},{"@type":"ListItem","position":2,"name":"La SATT IDF Innov soutient la conception d\u2019un vaccin anti-chlamydia, un enjeu mondial de sant\u00e9 publique"}]},{"@type":"WebSite","@id":"https:\/\/www.satt.fr\/en\/#website","url":"https:\/\/www.satt.fr\/en\/","name":"R\u00e9seau SATT","description":"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.satt.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/f31631111412086f92f3dd2a2e132823","name":"Estelle VIDAL","url":"https:\/\/www.satt.fr\/en\/author\/estelle\/"}]}},"_links":{"self":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/8533","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/users\/22"}],"replies":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/comments?post=8533"}],"version-history":[{"count":3,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/8533\/revisions"}],"predecessor-version":[{"id":8540,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/8533\/revisions\/8540"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media\/8530"}],"wp:attachment":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media?parent=8533"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/categories?post=8533"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/tags?post=8533"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}